Research & Development
Hologic awarded $19M by BARDA to develop COVID-19 assays to FDA IVD standards
Hologic announced that the funding will be used to bring its two COVID assays up to the FDA’s IVD standards.
November 2, 2022
Day Zero awarded $8.2 million in CARB-X funding
Day Zero is developing diagnostic tests that use genome sequencing and machine-learning algorithms to rapidly identify pathogens and their antibacterial-resistance profiles.
October 20, 2022
Diadem nabs $2.5M to further validate Alzheimer’s blood test
The two-year grant will enable Diadem, a company that has been developing a blood-based test for the early prediction of Alzheimer's disease (AD), to leverage data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), a longitudinal multicenter study designed to enable development of biomarkers for the early detection and tracking of AD.
September 6, 2022
VolitionRx prices $6M public offering
The company said that gross proceeds to Volition from the offering are expected to be $6 million. Volition also granted the underwriter a 30-day option to purchase up to an additional 450,000 shares of its common stock at the public offering price. The offering is expected to close on or about August 2.
July 28, 2022
AACR announces 2022 cancer research award recipients
The award recognizes female researchers who have made pioneering contributions to the understanding and treatment of breast and gynecological cancer. This year's awardees include:
April 3, 2022
Foundation Medicine secures FDA 'breakthrough' designation
The FDA granted the designation for use of the assay in detecting molecular residual disease (MRD) in early-stage cancer after curative therapy. These test results can then help to guide further treatment decisions in these patients, according to the vendor.
February 14, 2022
DNA forensic evidence frees Ohio man of rape, attempted rape
Low-value prostate cancer screening has Medicare spending ramifications, study finds
‘Good’ cholesterol worse for some adults: NIH study
Empatica receives FDA clearance for digital biomarker platform, closes Series B financing
PerkinElmer launches adeno-associated virus vector detection kits for research
Genabio Diagnostics COVID-19 self-test available on Amazon
SLAS 2022: 6 tips for scientists looking to start companies
1. Find the right team
February 8, 2022
Fla. university awarded $1.3M from NIH for HIV test
With the grant, FAU researchers hope to develop an affordable, disposable self-testing HIV-1 chip that can selectively detect HIV from whole blood samples. The researchers are aiming for an automated test that requires no refrigeration and can produce results within 40 minutes. They also said it will be sensitive enough to detect HIV during acute infection, treatment, and viral rebound, according to a press release issued by the university.
January 17, 2022
Siemens gets FDA nod for ELF test for liver fibrosis
ELF is a noninvasive blood test intended for use with the company's Advia Centaur XP immunoassay system. The test provides a numeric score that is automatically generated via an algorithm and is used to assess the likelihood of progressing to cirrhosis and liver-related clinical events in patients with severe or advanced fibrosis (F3 or F4) due to nonalcoholic steatohepatitis (NASH).
August 23, 2021
Researchers get $3.3M to study AI in oral cancer
The U.S. National Cancer Institute awarded the five-year grant to a group led by Anant Madabhushi, PhD, the Donnell Institute Professor of Biomedical Engineering at CWRU and head of the Center for Computational Imaging and Personalized Diagnostics, and Dr. James Lewis Jr., a pathology, microbiology, and immunology professor at Vanderbilt University Medical Center.
January 5, 2021
Liver cancer diagnostic test offers promise of early detection
The platform is called EV Click Chips, and the hope is that it will enable more effective purification of extracellular vesicles in blood from people with hepatocellular carcinoma. Researchers from the University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center have received a $2.97 million grant from the U.S. National Cancer Institute (NCI) to develop the technology further.
August 4, 2020
Blood biomarkers show risk for preeclampsia in pregnant women
The proof-of-concept study looked at the levels and ratio of the proteins FK506-binding protein like (FKBPL) and cluster of differentiation 44 (CD44) in plasma of pregnant women and matched normal controls at the Royal Jubilee Maternity Hospital in Belfast, U.K., and how they associated with risk for preeclampsia.
July 7, 2020
Page 1 of 3